Volume 124, Issue 3 , Pages 428-433, September 2009
Unmet needs in severe chronic upper airway disease (SCUAD)
Although the majority of patients with chronic upper airway diseases have controlled symptoms during treatment, many patients have severe chronic upper airway diseases (SCUADs). SCUAD defines those patients whose symptoms are inadequately controlled despite adequate (ie, effective, safe, and acceptable) pharmacologic treatment based on guidelines. These patients have impaired quality of life, social functioning, sleep, and school/work performance. Severe uncontrolled allergic rhinitis, nonallergic rhinitis, chronic rhinosinusitis, aspirin-exacerbated respiratory diseases, or occupational airway diseases are defined as SCUADs. Pediatric SCUADs are still unclear. In developing countries SCUADs exist, but risk factors can differ from those seen in developed countries. Comorbidities are common in patients with SCUADs and might increase their severity. The present document is the position of a group of experts considering that SCUADs should be considered differently from mild chronic upper airway diseases. It reviews the state of the art, highlighting gaps in our knowledge, and proposes several areas for a better understanding, prevention, and management of SCUADs. This document can also serve to optimize the pharmacoeconomic evaluation of SCUADs by means of comparison with mild chronic upper airway diseases.
Key words: Severe chronic upper airway disease, rhinitis, rhinosinusitis
Abbreviations used: AR, Allergic rhinitis, COPD, Chronic obstructive pulmonary disease, CRS, Chronic rhinosinusitis, CT, Computed tomography, NAR, Nonallergic rhinitis, SCUAD, Severe chronic upper airway disease
Disclosure of potential conflict of interest: J. Bousquet has received fees for lectures or participation on advisory boards from Stallergenes, Schering-Plough, UCB, Merck, Sanofi-Aventis, and Allmiral. T. B. Casale has received research support through his institution from Pfizer and Stallergenes. A. A. Cruz is a consultant for AstraZeneca; has received honoraria, travel grants, or other grants from Mantecorp, CHIESI, and Novartis; and has received research support from GlaxoSmithKline, Wellcome Trust, FAPESB (Brazil), and CNPq (National Research Council, Brazil). T. Zuberbier is a consultant for Schering-Plough, Novartis, Leti, Stallergenes, Bayer Schering, Ansell, Kryolan, UCB, Merck, Sharp & Dohme, and Procter & Gamble. The rest of the authors have declared that they have no conflict of interest.
PII: S0091-6749(09)00982-8
doi:10.1016/j.jaci.2009.06.027
© 2009 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Volume 124, Issue 3 , Pages 428-433, September 2009
